Schwarz, Par Go Head To Head Over Anxiety Drug

Law360, New York (May 3, 2006, 12:00 AM EDT) -- The patents for popular anti-anxiety drug Niravam have sparked a court battle between patent holder Schwarz Pharma and generics maker Par Pharmaceuticals.

Schwarz has filed a suit against Par in the U.S. District Court for the District of New Jersey, alleging that Par’s recently filed Abbreviated New Drug Application (ANDA) infringes Schwarz’s patents for a dissolving form of Alprazolam, the active ingredient in Niravam.

The complaint asserts two patents licensed to Schwarz by CIMA Labs Inc., both of which are entitled “Rapidly Dissolving Robust Dosage Form.”...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.